View Older Stories View More Recent Stories

Oct 7, 2019 06:37AM Capricor Therapeutics (CAPR) Reports Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy
Oct 7, 2019 06:30AM Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months
Oct 2, 2019 09:15AM Capricor to Present Interim Results from the HOPE-2 Trial in a Late Breaking Session of the World Muscle Society and Company to Host Conference Call Monday, October 7 at 5:30 AM PT / 8:30 AM ET
Sep 24, 2019 07:31AM Capricor Therapeutics (CAPR) to Meet with FDA to Discuss CAP-1002 to Treat DMD
Sep 24, 2019 07:30AM Capricor Therapeutics to Meet with FDA to Discuss CAP-1002 to Treat Duchenne Muscular Dystrophy
Sep 17, 2019 07:06AM Capricor Therapeutics (CAPR) to Present Results from HOPE-2 Trial of CAP-1002 in DMD in Late Breaking Session of World Muscle Society
Sep 17, 2019 07:00AM Capricor Therapeutics to Present Results from the HOPE-2 Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society
Sep 6, 2019 07:30AM Capricor Therapeutics to Present at Upcoming Conferences
Aug 6, 2019 04:00PM Capricor Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Jul 30, 2019 08:00AM Capricor Therapeutics to Present Second Quarter 2019 Financial Results and Recent Corporate Update on August 6
Jul 25, 2019 07:19AM Capricor Therapeutics (CAPR) Announces Positive DSMB Safety and Futility Review and Continuation of its HOPE-2 Study in DMD
Jul 25, 2019 07:00AM Capricor Therapeutics Announces Positive DSMB Safety and Futility Review and Continuation of its HOPE-2 Study in Duchenne Muscular Dystrophy
Jul 17, 2019 07:00AM Capricor Therapeutics and Parents Project Muscular Dystrophy to Host Webinar to Discuss Interim Analysis of the HOPE-2 Clinical Trial to Treat Patients with Duchenne Muscular Dystrophy
Jul 15, 2019 06:08AM Capricor Therapeutics (CAPR) Reports Positive Results from Interim Analysis in the HOPE-2 Trial
Jul 15, 2019 06:00AM Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy
May 13, 2019 04:00PM Capricor Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 6, 2019 04:00PM Capricor Therapeutics to Present First Quarter 2019 Financial Results and Recent Corporate Update on May 13
Mar 28, 2019 04:00PM Capricor Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Mar 21, 2019 08:00AM Capricor Therapeutics to Present Fourth Quarter and Full Year 2018 Financial Results and Recent Corporate Update on March 28
Feb 6, 2019 07:13AM Capricor Therapeutics (CAPR) Reports Continued Dosing of Enrolled Patients in HOPE-2 Clinical Trial for Duchenne Muscular Dystrophy
Feb 6, 2019 07:00AM Capricor Resumes Dosing of Enrolled Patients in HOPE-2 Clinical Trial for Duchenne Muscular Dystrophy
Jan 24, 2019 07:14AM Capricor (CAPR) Announces Neurology Published Study Reporting Significant Improvements in DMD Patients Treated with its Novel Cell Therapy
Jan 24, 2019 07:00AM Neurology Publishes Study Reporting Significant Improvements in Duchenne Muscular Dystrophy Patients Treated with Capricor’s Novel Cell Therapy
Jan 22, 2019 07:07AM Capricor Therapeutics (CAPR) Reports Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA
Jan 22, 2019 07:00AM Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA
Nov 13, 2018 04:01PM Capricor Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Nov 12, 2018 07:04AM Capricor Therapeutics (CAPR) to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical Trial
Nov 12, 2018 07:00AM Capricor to Meet with FDA under its RMAT Designation to Discuss HOPE-2 Clinical Trial
Nov 6, 2018 07:00AM Capricor Therapeutics to Present Third Quarter Financial Results and Corporate Update on November 13
Aug 21, 2018 07:00AM Capricor Therapeutics Presents Results of Studies of CAP-2003 at Gordon Research Conference on Extracellular Vesicles
Aug 9, 2018 04:00PM Capricor Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Aug 2, 2018 04:00PM Capricor Therapeutics to Present Second Quarter Financial Results and Corporate Update on August 9
Jul 17, 2018 07:00AM Capricor and USAISR Announce Collaboration to Investigate Exosome Platform to Treat Injured Troops
Jul 13, 2018 09:00AM Capricor Therapeutics and PPMD to Host Webinar for Duchenne Muscular Dystrophy Community on July 18
Jun 28, 2018 07:00AM Capricor Therapeutics to Present at PPMD Annual Conference
May 29, 2018 07:00AM Capricor Therapeutics to Present at the 2018 BIO International Convention in Boston
May 10, 2018 04:00PM Capricor Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update
May 4, 2018 08:00AM Capricor Therapeutics to Present First Quarter 2018 Financial Results and Corporate Update on May 10
May 3, 2018 07:00AM Capricor to Present on Exosomes at the Plenary Session of the International Society for Cellular Therapy in Montreal
Apr 30, 2018 07:00AM Capricor Announces Initiation of HOPE-2 Clinical Trial of CAP-1002 for Duchenne Muscular Dystrophy
Apr 30, 2018 07:00AM Capricor Announces Initiation of HOPE-2 Clinical Trial of CAP-1002 for Duchenne Muscular Dystrophy
Apr 19, 2018 07:06AM Capricor Therapeutics (CAPR) Reports New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model
Apr 19, 2018 07:00AM Capricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model
Apr 12, 2018 07:00AM Capricor to Provide Presentation at the Alliance for Regenerative Medicine’s Investor Day
Apr 6, 2018 10:00AM Capricor Therapeutics to Present at the MicroCap Conference on April 9, 2018
Mar 21, 2018 07:00AM Capricor Therapeutics to Present at Upcoming Oppenheimer and Needham Healthcare Conferences
Mar 14, 2018 04:00PM Capricor Presents Fourth Quarter and Full Year 2017 Financial Results and Corporate Update
Mar 8, 2018 04:00PM Capricor Therapeutics to Present Fourth Quarter and Full Year 2017 Financial Results and Corporate Update on Wednesday, March 14
Feb 28, 2018 08:00AM Capricor to Host Key Opinion Leader Lunch on March 9
Jul 27, 2017 09:26AM Pre-Open Stock Movers 07/27: (CAPR) (SHOR) (FB) Higher; (CUR) (AZN) (CYH) Lower (more...)
View More Recent Stories View Older Stories